-+ 0.00%
-+ 0.00%
-+ 0.00%
Can-Fite Completes Dosing in Interim-Analysis Cohort of Phase III Piclidenoson Psoriasis Trial
Share
Listen to the news
Can-Fite Completes Dosing in Interim-Analysis Cohort of Phase III Piclidenoson Psoriasis Trial
  • Can-Fite completed dosing in the first 247 patients in its pivotal Phase III trial of oral Piclidenoson for moderate-to-severe plaque psoriasis.
  • Interim results evaluating efficacy and safety are expected in the first quarter of 2027 following review by an independent monitoring committee.
  • The placebo-controlled trial is being conducted under a protocol agreed with the FDA and European Medicines Agency.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180700PRIMZONEFULLFEED9880291) on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending